Zealand Pharma, Eli Lilly sign obesity, diabetes research deal
COPENHAGEN Aug 29 (Reuters) - Danish pharmaceutical group Zealand Pharma said it had entered into a research and development agreement with U.S. drugmaker Eli Lilly and Co , with a focus on type two diabetes and obesity.
The companies will join efforts to design and develop potentially novel therapeutic peptides for type two diabetes and obesity, it said in a statement.
The collaboration could also be expanded into other disease areas, Zealand said.
- Radar showed missing plane may have turned back: Malaysia military
- Missing Malaysian jet may have disintegrated in mid-air: source |
- Malaysian plane presumed crashed; questions over false IDs |
- Exclusive: Malaysia plane probe narrows on mid-air disintegration - source